In search of novel and therapeutically significant melatoninergic ligands

Recent Patents on CNS Drug Discovery

Volumn 2, Issue 3, 2007, Pages 241-245

  Mody, Sejal M ^a   Hu, Yueqing ^a   Ho, Maurice K C ^a   Wong, Yung H ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Melatonin; Melatoninergic ligands; MT1 receptor; MT2 receptor; Patents; Ramelteon; Sleep disorders

Indexed keywords

2 IODOMELATONIN; 6 CHLOROMELATONIN; AGOMELATINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; BENZOFURAN DERIVATIVE; CARBAZOLE DERIVATIVE; DIHYDROBENZOFURAN DERIVATIVE; ESZOPICLONE; FLUORENE DERIVATIVE; HYPNOTIC AGENT; INDAN DERIVATIVE; LY 156735; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN DERIVATIVE; MELATONINERGIC LIGAND; N ACETYLSEROTONIN; NAPHTHALENE; PD 6735; PLACEBO; QUINOLINE DERIVATIVE; RAMELTEON; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEC 162; ZALEPLON; ZOLPIDEM TARTRATE; ZOPICLONE;

CEREBROVASCULAR ACCIDENT; CIRCADIAN RHYTHM; CLINICAL EVALUATION; CLINICAL TRIAL; DEGENERATIVE DISEASE; DEPRESSION; DIZZINESS; DROWSINESS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG STRUCTURE; DRUG WITHDRAWAL; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; INSOMNIA; MAMMAL; NEUROPROTECTION; NONHUMAN; PATENT; PRIORITY JOURNAL; REPRODUCTION; REVIEW; SEXUAL DYSFUNCTION; SLEEP DISORDER; SLEEP WAKING CYCLE; WITHDRAWAL SYNDROME;

ANIMALS; BIOMEDICAL RESEARCH; CIRCADIAN RHYTHM; HUMANS; LIGANDS; MELATONIN; RECEPTORS, MELATONIN; SLEEP DISORDERS;

EID: 36749066274     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488907782411756     Document Type: Review

References (91)

1. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12: 151-180.
2. Kennaway DJ, Wright H. Melatonin and circadian rhythms. Curr Top Med Chem 2002; 2: 199-209.
3. Iuvone PM, Tosini G, Pozdeyev N, Haque R, Klein DC, Chaurasia SS. Circadian clocks, clock networks, arylalkylamine N-acetyltransferase, and melatonin in the retina. Prog Retin Eye Res 2005; 24: 433-456.
4. Doolen S, Krause DN, Dubocovich ML, Duckles SP. Melatonin mediates two distinct responses in vascular smooth muscle. Eur J Pharmacol 1998; 345: 67-69.
5. Guerrero JM, Reiter RJ. Melatonin-immune system relationships. Curr Top Med Chem 2002; 2: 167-79.
6. Cuzzocrea S, Reiter RJ. Pharmacological actions of melatonin in acute and chronic inflammation. Curr Top Med Chem 2002; 2: 153-165.
7. Blask DE, Sauer LA, Dauchy RT, Holowachuk EW, Ruhoff MS, Kopff HS. Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events. Cancer Res 1999; 59: 4693-4701.
8. Cardinali DP, Ladizesky MG, Boggio V, Cutrera RA, Mautalen C. Melatonin effects on bone: experimental facts and clinical perspectives. J Pineal Res 2003; 34: 81-87.
9. Bubenik GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 2002; 47: 2336-2348.
10. Reiter RJ, Tan DX, Manchester LC, Qi W. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. Cell Biochem Biophys 2001; 34(2): 237-56.
11. Hussein MR, Ahmed OG, Hassan AF, Ahmed MA. Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: an animal model. Int J Exp Pathol 2007; 88(1): 19-29.
12. Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994; 113: 1177-1185.
13. Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gusella JF. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci USA 1995; 92: 8734-8738.
14. New DC, Tsim ST, Wong YH. G protein-linked effector and second messenger systems involved in melatonin signal transduction. Neurosignals 2003; 2: 59-70.
15. Witt-Enderby PA, Bennett J, Jarzynka MJ, Firestine S, Melan MA. Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci 2003; 72: 2183-2198.
16. Yung LY, Tsim ST, Wong YH. Stimulation of cAMP accumulation by the cloned Xenopus melatonin receptor through Gi and Gz proteins. FEBS Lett 1995; 372: 99-102.
17. Chan AS, Lai FP, Lo RK, Voyno-Yasenetskaya TA, Stanbridge EJ, Wong YH. Melatonin MT1 and MT2 receptors stimulate c-Jun N-terminal kinase via pertussis toxin-sensitive and -insensitive G proteins. Cell Signal 2002; 14: 249-57.
18. Nosjean O, Ferro M, Coge F, et al. Identification of the Melatonin-binding Site MT3 as the Quinone Reductase 2. J Biol Chem 2000; 275(40): 31311-31317.
19. 3. FEBS Lett 2004; 578: 116-120.
20. Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother 2006; 60: 97-108.
21. Dubocovich ML, Yun K, Al-Ghoul WM, Benloucif S, Masana MI. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J 1998; 12: 1211-20.
22. 1 (Mel 1a) is associated with melatonin-induced enhancement of cell-mediated and humoral immunity. Neuroendocrinology 2001; 74: 178-184.
23. 1) knockout mice display depression-like behaviors and deficits in sensorimotor gating. Brain Res Bull 2006; 68: 425-429.
24. von Gall C, Weaver DR, Mock J, Jilg A, Stehle JH, Korf HW. Melatonin plays a crucial role in the regulation of rhythmic clock gene expression in the mouse pars tuberalis. Ann N Y Acad Sci 2005; 1040: 508-511.
25. Hunt AE, Al-Ghoul WM, Gillette MU, Dubocovich ML. Activation of MT2 melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol 2001; 280: 110-118.
26. Rosenthal NE, Sack DA, Jacobsen FM, et al. Melatonin in seasonal affective disorder and phototherapy. J Neural Transm Suppl 1986; 21: 257-267.
27. Nakagawa H, Sack RL, Lewy AJ. Sleep propensity free-runs with the temperature, melatonin and cortisol rhythms in a totally blind person. Sleep 1992; 15: 330-336.
28. Sack RL, Blood ML, Lewy AJ. Melatonin rhythms in night shift workers. Sleep 1992; 15:434-441.
29. Arendt J. Melatonin in humans: jet lag and after. Adv Pineal Res 1991; 5: 299-302.
30. Lee E-J, Lee M-Y, Chen H-Y, et al. Melatonin attenuates gray and white matter damage in a mouse model of transient focal cerebral ischemia. J Pineal Res 2005; 38: 42-52.
31. Khaldy H, Escames G, Leon J, Bikjdaouene L, Acuna-Castroviejo D. Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion. Neurobiol Aging 2003; 24: 491-500.
32. Mayo JC, Sainz RM, Tan DX, Antolín I, Rodríguez C, Reiter RJ. Melatonin and Parkinson's disease. Endocrine 2005; 27: 169-78.
33. Maurizi CP. Alzheimer's disease: roles for mitochondrial damage, the hydroxyl radical and cerebrospinal fluid deficiency of melatonin. Med Hypotheses 2001; 57: 455-462.
34. Cardinali DP. Clinical perspectives for the use of melatonin as a neuro-protective chronobiotic in Alzheimer's disease. Akualnosci Neurologiczne 2003; 2: 188-204.
35. 2 melatonin receptor expression in Alzheimer's disease. J Pineal Res 2005; 38: 10-16.
36. Kilic U, Kilic E, Reiter RJ, Bassetti CL, Hermann DM. Signal transduction pathways involved in melatonin-induced neuroprotection after focal cerebral ischemia in mice. J Pineal Res 2005; 38: 67-71.
37. Macleod MR, O'Collins T, Horky LL, Howells DW, Donnan GA. Systemic review and meta-analysis of the efficacy of melatonin in experimental stroke. J Pineal Res 2005; 38: 35-41.
38. Pei Z, Cheung RT. Pretreatment with melatonin exerts anti-inflammatory effects against ischemia/reperfusion injury in a rat middle cerebral artery occlusion stroke model. J Pineal Res 2004; 37: 85-91.
39. Molina-Carballo A, Muñoz-Hoyos A, Reiter RJ, et al. Utility of high doses of melatonin as adjunctive therapy in a child with severe myoclonic epilepsy: two years' experience. J Pineal Res 1997; 27: 202-209.
40. Bikjdaouene L, Escames G, León J, et al. Changes in brain amino acids and nitric oxide after melatonin administration in rats with pentylenetetrazole-induced seizures. J Pineal Res 2003; 25: 54-60.
41. Acuña-Castroviejo D, Escames G, Macías M, et al. Cell protective role of melatonin in the brain. J Pineal Res 1995; 16: 100-112.
42. Uchikawa O, Fukatsu K, Tokunoh R, et al. Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists. J Med Chem 2002; 45: 4222-39.
43. 1251]-iodomelatonin to characterize melatonin sites in chicken retina. Proc Natl Acad Sci USA 1987; 84: 3916-3920.
44. Sugden D, Chongn NW, Lewis DF. Structural requirements at the melatonin receptor. Br J Pharmacol 1995; 114: 618-623.
45. Chong NW, Evans JE, Sugden D. N-bromoacetyl 5-methoxytryptamine: an irreversible melatonin ligand, Biochem Biophys Res Commun 1993; 193: 1355-1361.
46. Mor M, Rivara S, Silva C. Melatonin receptor ligands: synthesis of new melatonin derivatives and comprehensive comparative molecular field analysis (CoMFA) study. J Med Chem 1998; 41: 3831-3844.
47. Sicsic S, Serraz I, Andrieux J, et al. Three-dimensional quantitative structure-activity relationship of melatonin receptor ligands: a comparative molecular field analysis study. J Med Chem 1997; 40: 739-748.
48. Grol CJ, Jansen JM. The high affinity melatonin binding site probed with conformationally restricted ligands - II. Homology modeling of the receptor. Bioorg Med Chem 1996; 4: 1333-1339.
49. Spadoni G, Stankov B, Duranti A, et al. 2-Substituted 5-methoxy- N-acyltryptamines: synthesis, binding affinity for the melatonin receptor, and evaluation of the biological activity. J Med Chem 1993; 36: 4069-4074.
50. Zlotos DP. Recent advances in melatonin receptor ligands. Arch Pharm Chem Life Sci 2005; 338: 229-247.
51. Horn, A.S., Dubocovich, M.L.: US5071875 (1991).
52. Horn, A.S., Dubocovich, M.L.: US5151446 (1992).
53. Lesieur, D., Yous, S., Depreux, P., Andrieux, J., Adam, G., Caignard, D.H., Guardiola, B.: US5276051 (1994).
54. Yous, S., Lesieur, D., Depreux, P., Guardiola-Lemaitre, B., Adam, G., Renard, P., Caignard, D.H.: US5420158 (1995).
55. Yous, S., Lesieur, D., Depreux, P., Guardiola-Lemaitre, B., Adam, G., Renard, P., Caignard, D.H.: US19975616614 (1997).
56. Fourtillan, J., Fourtillan, M., Jacquesy, J., Jouannetaud, M., Violeau, B., Karam, O.: US6048868 (1996).
57. Takaki, K.S., Karageorge, G.N., Keavy, D.J., Parker, M.F.W., Brett, T.: US5541228 (1996).
58. Takaki, K.S., Karageorge, G.N., Keavy, D.J, Parker, M.F., Watson, B.T.: US5661185 (1997).
59. Watson, B.T., Takaki, K.S., Yevich, J.P., Epperson, J.R., Karageorge, G.N., Leboulluec, K.L.: US5736578 (1998).
60. Leboulluec, K.L., Takaki, K.S.: WO9852554 (1998).
61. Leboulluec, K.L., Takaki, K.S.: US20006028112 (2000).
62. Takaki, K.S., Watson, B.T., Poindexter, G.S., Epperson, J.R.: US5661186 (1997).
63. Mattson, R.J., Cart, J.D.: US5780470 (1998).
64. Mattson, R.J., Catt, J.D.: US5703239 (1997).
65. Takaki, K.S., Bruce, M., Poindexter, G.S., Watson, B.T., Yevich, J.P.: EP0771791A1 (1997).
66. Takaki, K.S., Bruce, M.A., Poindexter, G.S., Watson, B.T., Yevich, J.P.: US5677328 (1997).
67. Ohkawa, S., Uchikawa, O., Miyamoto, M.: US5708005 (1998).
68. Dubowchik, G.M., Ditta, J.L., Bertenshaw, S.R.: US20056908931 (2005).
69. Poissonnier-Durieux, S., Wallez, V., Gasnereau, A., Yous, S., Lesieur, D., Delagrange, P., Renard, P., Bennejean, C., Boutin, J., Audinot, V.: US20077214689 (2007).
70. Catt, J.D., Johnson, G., Keavy, D.J., Mattson, R.J., Parker, M.F., Takaki, K.S., Yevich, J.P.: US5856529 (1999).
71. Catt, J.D., Johnson, G., Keavy, D.J., Mattson, R.J., Parker, M.F., Takaki, K.S., Yevich, J.P.: WO059825606A1 (2005).
72. Stack, G.P., Gross, J.L.: WO06116136 (2006).
73. Catt, J.D., Johnson, G., Keavy, D.J., Mattson, R.J., Parker, M.F., Takaki, K.S., Yevich, J.P.: US20006060506 (2000).
74. Takaki, ICS., Sun, L., Johnson, G., Epperson, J.R., Bertenshaw, S.R.: US20036569894 (2003).
75. Viaud, M., Guillaumet, G., Daubos, P., Bennejean, C., Delagrange, P., Renard, P.: US20036620809 (2003).
76. Takaki, K.S., Sun, L., Johnson, G., Bertenshaw, S.R., Denhart, D., Chen, J.: US20046737431 (2004).
77. Guillaumet, G., Viaud, M., Van De Poel, H., Delagrange, P., Bennejean, C., Renard, P.: US20036667304 (2003).
78. Mattson, R.J., Catt, J.D., Keavy, D.J.: US5530012 (1996).
79. Epperson, J.R., Yevich, J.P.: WO9738682 (1997).
80. Epperson, J.R., Yevich, J.P.: US5808151 (1998).
81. Viaud, M., Guillaumet, G., Mazeas, D., Vandepoel, H., Renard, P., Pfeiffer, B., Delagrange, P.: US5714495 (1998).
82. Chen, J., Dextraze, P., Dodier, M., Takaki, K.S.: WO999962515 (1999).
83. Epperson, J.R.: US20006090854 (2000).
84. Lesieur, D., Yous, S., Descamps-Francois, C., Lefoulon, F., Guillaumet, G., Viaud, M., Bennejean, C., Delagrange, P., Renard, P.: US20036635650 (2003).
85. Descamps-Francois, C., Yous, S., Lesieur, D., Guillaumet, G., Viaud, M., Da Costa, H., Bennejean, C., Delagrange, P., Renard, P.: US20077161035 (2007).
86. Depreux, P., Yous, S., Cheve, G., Guillaumet, G., Viaud, M., Larraya, C., Bennejean, C., Delagrange, P., Renard, P., Descamps-Francois, C.: US20016310074 (2001).
87. Dubowchik, G.M., Ditta, J.L., Bertenshaw, S.R.: US20056908931 (2005).
88. Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 2006; 63: 1149-57.
89. 2- receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005; 28: 303-307.
90. Zemlan FP, Mulchahey J, Scharf MB, Mayleben DW, Rosenberg R, Lankford A. The efficacy and safety of the melatonin agonist, β-methyl-6-chloromelatonin, in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psych 2005; 66: 384-390.
91. Lerchl A, Partsch CJ, Nieschlag E. Circadian and ultradian variations of pituitary and pineal hormones in normal men: evidence for a link between melatonin, gonadotropin, and prolactin secretion. J Pineal Res 1995; 18: 41-48.